$4.27
-0.03 (-0.70%)
Open$4.40
Previous Close$4.30
Day High$4.50
Day Low$4.18
52W High$71.50
52W Low$3.18
Volume—
Avg Volume46.9K
Market Cap5.14M
P/E Ratio—
EPS$-25.77
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+620.6% upside
Current
$4.27
$4.27
Target
$30.77
$30.77
$21.48
$30.77 avg
$35.71
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.39M | 59.60M | 759.7K |
| Net Income | -1,407,587,770 | -4,105,084,228 | -24,634 |
| Profit Margin | -7,652.8% | -7,270.1% | -3.2% |
| EBITDA | -1,182,760,510 | -3,641,032,030 | -38,889 |
| Free Cash Flow | — | — | -29,815 |
| Rev Growth | -69.1% | -69.1% | +6.1% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |